HK Stock Market Move | XIZHI TECH-P (01879) surged over 11% as Scale-up OCS becomes the core growth engine. The company is expected to enter the A-share market this month.
Xizhi Technology-P (01879) opened high today and continued to rise, with an increase of 11.22% as of this writing, priced at HKD 370.6, with a transaction volume of HKD 58.9573 million.
XIZHI TECH-P (01879) opened higher today and continued to rise, with an increase of 11.22% as of the time of publication, reaching HKD 370.6 and a trading volume of HKD 58.9573 million.
In the first half of this year, Xizhi Technology achieved a revenue of HKD 79.779 million, a year-on-year increase of 284%, with a comprehensive gross margin of approximately 65.8%, and an adjusted net loss of HKD 147 million. The revenue from the optical interconnection business was HKD 60.70 million, an increase of 275%, primarily driven by the larger-scale commercial deployment of Scale-up OCS. Sealand stated that as one of the few independent Scale-up optical interconnection solution providers in China capable of large-scale commercialization, it will benefit from the development of supernodes and Scale-up.
Additionally, the Hang Seng Index Company previously announced the semi-annual index adjustment results, in which Xizhi Technology was included in the Hang Seng Composite Index. All changes will be implemented after the market close on September 4 and will take effect from September 7, at which point the Shanghai and Shenzhen stock exchanges will adjust the scope of investable stocks under the Hong Kong Stock Connect accordingly. According to forecasts from institutions such as Huatai and CICC, Xizhi Technology is expected to be included in the Hong Kong Stock Connect in early September.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





